Abstract
Background: Gut microbiota play a vital role not only in the digestion and absorption of nutrients, but also in homeostatic maintenance of host immunity, metabolism and the gut barrier. Recent evidence suggests that gut microbiota alterations contribute to the pathogenesis of metabolic disorders.
Objective and Method: In this review, we discuss the association between the gut microbiota and metabolic disorders, such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease, and the contribution of relevant modulating interventions, focusing on recent human studies.
Results: Several studies have identified potential causal associations between gut microbiota and metabolic disorders, as well as the underlying mechanisms. The effects of modulating interventions, such as prebiotics, probiotics, fecal microbiota transplantation, and other new treatment possibilities on these metabolic disorders have also been reported.
Conclusion: A growing body of evidence highlights the role of gut microbiota in the development of dysbiosis, which in turn influences host metabolism and disease phenotypes. Further studies are required to elucidate the precise mechanisms by which gut microbiota-derived mediators induce metabolic disorders and modulating interventions exert their beneficial effects in humans. The gut microbiota represents a novel potential therapeutic target for a range of metabolic disorders.
Keywords: Gut microbiota, obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, prebiotics, probiotics, fecal microbiota transplantation.
Current Medicinal Chemistry
Title:Gut Microbiota as a Therapeutic Target for Metabolic Disorders
Volume: 25 Issue: 9
Author(s): Hirofumi Okubo, Yusuke Nakatsu, Akifumi Kushiyama, Takeshi Yamamotoya, Yasuka Matsunaga, Masa-ki Inoue, Midori Fujishiro, Hideaki Sakoda, Haruya Ohno, Masayasu Yoneda, Hiraku Ono and Tomoichiro Asano*
Affiliation:
- Department of Medical Chemistry, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima,Japan
Keywords: Gut microbiota, obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, prebiotics, probiotics, fecal microbiota transplantation.
Abstract: Background: Gut microbiota play a vital role not only in the digestion and absorption of nutrients, but also in homeostatic maintenance of host immunity, metabolism and the gut barrier. Recent evidence suggests that gut microbiota alterations contribute to the pathogenesis of metabolic disorders.
Objective and Method: In this review, we discuss the association between the gut microbiota and metabolic disorders, such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease, and the contribution of relevant modulating interventions, focusing on recent human studies.
Results: Several studies have identified potential causal associations between gut microbiota and metabolic disorders, as well as the underlying mechanisms. The effects of modulating interventions, such as prebiotics, probiotics, fecal microbiota transplantation, and other new treatment possibilities on these metabolic disorders have also been reported.
Conclusion: A growing body of evidence highlights the role of gut microbiota in the development of dysbiosis, which in turn influences host metabolism and disease phenotypes. Further studies are required to elucidate the precise mechanisms by which gut microbiota-derived mediators induce metabolic disorders and modulating interventions exert their beneficial effects in humans. The gut microbiota represents a novel potential therapeutic target for a range of metabolic disorders.
Export Options
About this article
Cite this article as:
Okubo Hirofumi , Nakatsu Yusuke , Kushiyama Akifumi , Yamamotoya Takeshi , Matsunaga Yasuka , Inoue Masa-ki , Fujishiro Midori, Sakoda Hideaki , Ohno Haruya , Yoneda Masayasu, Ono Hiraku and Asano Tomoichiro*, Gut Microbiota as a Therapeutic Target for Metabolic Disorders, Current Medicinal Chemistry 2018; 25(9) . https://dx.doi.org/10.2174/0929867324666171009121702
DOI https://dx.doi.org/10.2174/0929867324666171009121702 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Steered Molecular Dynamics-A Promising Tool for Drug Design
Current Bioinformatics Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Virtual Screening Based Discovery of PTP1B Inhibitors and Their Biological Evaluations
Letters in Drug Design & Discovery Cervicocranial Arterial Dissection: An Analysis of the Clinical Features, Prognosis, and Treatment Efficacy
Current Neurovascular Research Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury
Current Alzheimer Research Epidemiology of Diabetes Mellitus in the United Arab Emirates
Current Diabetes Reviews The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Buxus sempervirens L Improves Streptozotocin-induced Diabetes Mellitus in Rats
Cardiovascular & Hematological Disorders-Drug Targets Requirements and Perspectives for Integrating Metabolomics with other Omics Data
Current Metabolomics Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe
Current HIV Research Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Modulation of Hematological Indices of Normal and Alloxan-Induced Diabetic Rabbits by Aqueous Extract of Pleurotus tuberregium Sclerotia
Endocrine, Metabolic & Immune Disorders - Drug Targets Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA Nonfasting Hyperlipidemia and Cardiovascular Disease
Current Drug Targets Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives
Mini-Reviews in Medicinal Chemistry Fat and Aging: A Tale of Two Tissues
Current Aging Science Diabetes, Cancer and Treatment – A Mini-Review
Current Drug Safety Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology